The clinical trial industry faces a persistent and costly challenge: poor site selection. With up to 85% of trials failing to meet enrollment targets due in part to suboptimal site identification, the path from promising therapeutic concept to patient access remains unnecessarily complicated.
Today, we’re proud to announce that our TriNetX LIVE™ platform was recognized as a Best of Show Finalist at the SCOPE Europe conference, honoring our commitment to revolutionizing how organizations approach clinical trial site selection through intelligent, data-driven solutions.
The Problem: Site Selection Complexity at Scale
Clinical trial site selection remains one of the most critical yet challenging aspects of study planning. Traditional approaches rely on fragmented data sources, outdated site intelligence, and manual processes that create significant inefficiencies and recruitment delays.
Key challenges include:
- Fragmented Site Intelligence: Site performance data is scattered across multiple systems with inconsistent identification standards, making it difficult to get a complete picture of any single site’s capabilities.
- Limited Historical Context: Organizations lack visibility into sites’ clinical trial experience, therapeutic expertise, and principal investigator (PI) networks, forcing them to make decisions without crucial context.
- Capacity Visibility: There are no real-time insights into site availability and current trial loads, leading to overburdened locations and missed opportunities at available sites.
- Geographic Inefficiency: Users lack the ability to visualize and optimize site distribution for patient accessibility and recruitment success.
These challenges result in extended study startup timelines, suboptimal site selection, and ultimately delayed patient access to innovative treatments. Sponsors and contract research organizations (CROs) waste valuable time manually cross-referencing databases, while healthcare organizations struggle to showcase their capabilities and connect with relevant opportunities.
The problem is further compounded by the lack of standardized site identification across platforms, creating confusion and administrative burden when matching internal systems with external databases. As the TriNetX network continues to expand globally, the increasing scale and complexity of site selection now call for more sophisticated, data-driven approaches.
Introducing TriNetX Site Profiles: Intelligence Made Actionable
TriNetX Site Profiles create a clear pathway to clinical trial site intelligence, transforming how organizations evaluate and select sites through comprehensive, data-driven insights integrated directly into TriNetX LIVE™.
Site Profiles introduces five core capabilities designed to address the most pressing challenges in site selection:
- Historical Performance Analytics provides five-year trial volume data sourced from public databases (primarily NCBI), giving users insight into sites’ track records.
- Real-time Capacity Monitoring displays current active trial counts to assess site availability and workload.
- Therapeutic Expertise Mapping reveals indication-specific trial counts, allowing users to identify sites with genuine specialization in relevant therapeutic areas.
- PI Directory Integration surfaces comprehensive lists of known PIs with trial experience at each site, unlocking valuable investigator intelligence.
- Interactive Site Profiles provide an intuitive interface accessible from the TriNetX LIVE™ Site Dashboard with instant access to key metrics.
The Innovation Behind the Solution
What makes Site Profiles genuinely innovative is the sophisticated technology architecture that powers these capabilities through seamless integration of public clinical trial databases with real-world patient data.
Multi-Source Data Harmonization employs advanced algorithms that cross-reference site names across TriNetX’s network with third-party public databases. This automatic matching and validation process creates unified profiles with unprecedented depth, solving a problem that previously required manual research and external validation.
Golden Number Standardization represents perhaps the most significant innovation. By integrating with DrugDev Golden Numbers, Site Profiles eliminates the industry’s long-standing site standardization problem. These standardized global identifiers enable seamless data matching across multiple platforms and internal systems, which is a capability that has been missing from the industry for years.
Real-Time Intelligence Layer dynamically combines historical performance metrics with current capacity indicators and therapeutic expertise mapping, creating actionable site selection intelligence that evolves with your network.
Scalable Architecture is built to handle massive data volumes across 133M+ patients at 9,200+ sites in 15+ countries (51% YTD growth), with API-first design enabling programmatic access for enterprise integration workflows.
Unlocking Principal Investigator Intelligence surfaces valuable PI expertise and site capabilities by leveraging publicly available information, enabling discovery and connection without compromising patient privacy.
Geographic Visualization Integration with TriNetX’s interactive site map enables users to visualize trial experience geographically while drilling down into specific site capabilities.
Impact Where It Matters Most
The practical implications of Site Profiles are substantial. Organizations can now dramatically reduce study startup timelines by making informed site selection decisions in a fraction of the traditional time. The data-driven approach optimizes site performance by ensuring better matches between study requirements and site capabilities. Most importantly, by accelerating the pathway from site selection to active recruitment, Site Profiles ultimately helps get innovative treatments to patients faster.
The Path Forward
Recognition as a Best of Show Finalist at SCOPE Europe reflects the significance of the problem Site Profiles solves and the quality of the solution TriNetX has built. The clinical trial industry doesn’t need incremental improvements to manual processes; it needs intelligent, data-driven tools that fundamentally transform how professionals approach their work.
Site Profiles represents exactly that kind of innovation: a leap forward from fragmented, manual site selection toward intelligent decision-making that benefits sponsors, CROs, healthcare organizations, and most importantly, patients waiting for access to innovative treatments.
TriNetX LIVE™ continues to evolve as the industry’s trusted network for clinical trial professionals. We’re committed to delivering solutions that address real challenges and create measurable impact across the clinical development ecosystem.